AstraZeneca Advances Scientific Leadership Across Multiple Cancers With First Data From Four Pivotal Phase III Trials at ESMO
October 12, 2023
October 12, 2023
WILMINGTON, Delaware, Oct. 12 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca including two late-breaking Presidential Symposia an . . .
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 20-24, 2023.
Nearly 100 abstracts will feature 19 approved and potential new medicines from AstraZeneca including two late-breaking Presidential Symposia an . . .